Hologic (NASDAQ:HOLX) Price Target Lowered to $90.00 at Leerink Partners

Hologic (NASDAQ:HOLX) had its price objective cut by Leerink Partners from $95.00 to $90.00 in a research report sent to investors on Tuesday morning, Benzinga reports. They currently have an outperform rating on the medical equipment provider’s stock.

Several other analysts also recently commented on HOLX. JPMorgan Chase & Co. upped their price objective on Hologic from $91.00 to $95.00 and gave the company an overweight rating in a research note on Tuesday, July 30th. Evercore ISI upped their price target on Hologic from $78.00 to $82.00 and gave the stock an in-line rating in a research note on Tuesday, October 1st. Citigroup lowered shares of Hologic from a buy rating to a neutral rating and lowered their price objective for the company from $95.00 to $85.00 in a research report on Tuesday, October 1st. Mizuho boosted their price objective on shares of Hologic from $85.00 to $90.00 and gave the company an outperform rating in a research note on Friday, October 4th. Finally, StockNews.com cut shares of Hologic from a strong-buy rating to a buy rating in a research note on Friday, September 27th. Five research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of Moderate Buy and a consensus target price of $87.50.

Hologic Trading Down 0.1 %

NASDAQ:HOLX opened at $79.81 on Tuesday. The company has a market capitalization of $18.54 billion, a PE ratio of 27.15, a P/E/G ratio of 2.89 and a beta of 0.98. Hologic has a 52-week low of $64.02 and a 52-week high of $84.67. The stock’s 50 day moving average price is $81.06 and its 200 day moving average price is $77.57. The company has a quick ratio of 3.32, a current ratio of 3.99 and a debt-to-equity ratio of 0.51.

Hologic (NASDAQ:HOLX) last announced its earnings results on Monday, July 29th. The medical equipment provider reported $1.06 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.02 by $0.04. Hologic had a net margin of 17.59% and a return on equity of 19.53%. The business had revenue of $1.01 billion for the quarter, compared to analyst estimates of $1 billion. During the same period last year, the firm posted $0.93 earnings per share. The company’s revenue for the quarter was up 2.7% compared to the same quarter last year. On average, research analysts anticipate that Hologic will post 4.09 EPS for the current year.

Insider Buying and Selling at Hologic

In other news, Director Christiana Stamoulis sold 9,039 shares of the business’s stock in a transaction that occurred on Wednesday, July 17th. The stock was sold at an average price of $79.50, for a total transaction of $718,600.50. Following the sale, the director now owns 45,472 shares of the company’s stock, valued at $3,615,024. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, Director Christiana Stamoulis sold 9,039 shares of the firm’s stock in a transaction on Wednesday, July 17th. The stock was sold at an average price of $79.50, for a total value of $718,600.50. Following the completion of the transaction, the director now owns 45,472 shares in the company, valued at $3,615,024. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Brandon Schnittker sold 476 shares of the business’s stock in a transaction dated Tuesday, August 6th. The stock was sold at an average price of $83.11, for a total transaction of $39,560.36. Following the completion of the sale, the insider now owns 3,735 shares in the company, valued at $310,415.85. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 18,280 shares of company stock valued at $1,469,973. Corporate insiders own 1.75% of the company’s stock.

Institutional Trading of Hologic

Several large investors have recently modified their holdings of the business. Innealta Capital LLC purchased a new stake in Hologic during the 2nd quarter worth about $25,000. iA Global Asset Management Inc. acquired a new position in shares of Hologic in the first quarter valued at approximately $37,000. Sunbelt Securities Inc. purchased a new position in shares of Hologic during the second quarter valued at approximately $37,000. Cranbrook Wealth Management LLC acquired a new stake in Hologic during the second quarter worth approximately $47,000. Finally, Mather Group LLC. acquired a new stake in Hologic during the first quarter worth approximately $48,000. 94.73% of the stock is currently owned by institutional investors and hedge funds.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.